Kornimate/medical-research-clean huggingface dataset:
transcranial stimulation (tdcs) for the treatment of neuropathic facial pain

Conditions: Facial Pain

Summary: a study to determine if transcranial direct current stimulation (tdcs, the device that regulates brain activity, can improve pain in people with neuropathic facial pain and compare which modality (inhibitory tdcs over the somatosensory cortex or excitatory tdcs over the motor cortex) can result in better pain-relief.)

this is a pilot study designed to collect preliminary data on safety and efficacy of transcranial direct current stimulation (tdcs)to relieve pain in subjects with neuropathic facial pain,and to compare two pain-treatment tdcs modalities: inhibitory tdcs stimulation over the somatosensory cortex and excitatory tdcs over the motor cortex.

Eligibility criteria:
inclusion criteria: * spontaneous facial neuropathic pain due to any of following: 1. trigeminal neuralgia, type 1, (tn1): facial pain of spontaneous onset with predominantly episodic pain. 2. trigeminal neuralgia, type 2, (tn2): facial pain of spontaneous onset with predominantly constant pain. 3. trigeminal neuropathic pain, (tnp): facial pain resulting from unintentional injury to the trigeminal system from facial trauma, oral surgery, ear, nose and throat (ent) surgery, root injury from posterior fossa or skull base surgery, stroke, etc. 4. trigeminal deafferentation pain, (tdp): facial pain in a region of trigeminal numbness resulting from intentional injury to the trigeminal system from neurectomy, gangliolysis, rhizotomy, nucleotomy, tractotomy, or other denervating procedures. 5. symptomatic trigeminal neuralgia, (stn): facial pain resulting from multiple sclerosis. e) postherpetic neuralgia, (phn): facial pain resulting from trigeminal herpes zoster (shingles) outbreak in the trigeminal distribution. * pain intensity score for "worst pain in the last 24 hours" \>4 on a numeric scale 0-10 at the time of enrollment and before the first stimulation of each treatment block. * pain intensity score for "pain right now" \>4 on a numeric scale 0-10 before the first stimulation of each block of treatment. exclusion criteria: * uncontrolled hypertension, uncontrolled diabetes, uncontrolled cardiovascular disease * other painful conditions than neuropathic facial pain, that are not related to and can't be distinguished from the neuropathic facial pain * pregnancy * implanted neurostimulation devices (e.g. a spinal cord stimulator, a deep brain stimulator, etc) * active illegal drug/alcohol abuse * unable to follow directions or complete tools in english.

Keywords: tdcs neuropathic facial pain neuralgia deafferentation trigeminal
long term follow-up of traumatic fracture patients treated with integrated complementary and alternative medicine: observational study

Conditions: Fractures, Bone; Medicine, Korean Traditional

Summary: the purpose of this study is to reveal the effectiveness of integrative korean medicine for trauma fracture by observation inpatients treated with integrative korean medicine. this study is a prospective observational study. the subjects for study are patients diagnosed with fracture and who have been admitted to five jaseng hospital of korean medicine (gangnam, bucheon, daejeon, bundang and haeundae) for 2017.03-2020.08. medical records of selected patients will be analyzed, and online google surveys(or telephone) will be conducted for each patient. the survey questions are numeric rating scale (nrs), quality of life, and patient global impression of change (pgic), etc.


Eligibility criteria:
inclusion criteria: 1. 19-85 years old 2. pateints who have been admitted to five jaseng hospital of korean medicine (gangnam, bucheon, daejeon, bundang and haeundae) and hospitalized 5 days or more 3. fracture caused by trauma 4. patients have agreed to participate the study. exclusion criteria: 1. pathological fracture, stress fracture 2. open fracture 3. the cause of pain is due to other disease, not the fracture: tumors, fibromyalgia, rheumatoid arthritis, gout, etc. 4. patients who are difficult to complete the research questionaire because of communication, mental or physical capabilities. 5. lack of data of collection 6. patients deemed unable to participate in the clinical research by other researchers

Keywords: acupuncture therapy herbal medicine
h.pylori ttt with rebamipide

Conditions: H.Pylori Infection

Summary: the primary aim is specially in resistant cases of h.pylori and in promotion of peptic ulcer

helicobacter pylori infection is the main cause of peptic ulcer (1, 2) some consensus conferences have recommended triple therapy with a proton pump inhibitor (ppi) and two types of antibiotics for 7 days as first-line treatment when patients with peptic ulcer have helicobacter pylori infection.(3, 4)this recommendation is based on the finding that patients with proven eradication of h. pylori have an extremely low rate of recurrence of peptic ulcer.(5) although a well-controlled study found comparable rates of small gastric ulcer healing after eradication therapy alone without continuation of antiulcer treatment, relief of symptoms was significantly slower with eradication therapy alone. moreover, the success rate of eradication therapy has decreased during the past few decades, and whether or not eradication is successful becomes clear only 2-4 weeks after treatment(6). patients with large gastric ulcer lesions are often not completely healed with h. pylori eradication alone (7) . proton pump inhibitors (ppis) have become the mainstay of maintenance therapy after eradication of h. pylori infection due to the associated effective healing and fast relief of symptoms without tachyphylaxis. however, ppi therapy has some risks, including dyspeptic symptom or rebound acid hypersecretion after cessation that may induce dependence (8,9) , drug interactions with other substrate of cyp2c19, and some kinds of respiratory or gastrointestinal infections . also, the result of h. pylori eradication can be affected by such antisecretory drugs.(10) rebamipide is a gastroprotective antiulcer drug that has been found to reduce the rate of recurrence of gastric ulcers without affecting h. pylori status, unlike antisecretory drugs such as ppis and h2 receptor antagonists.6 and have a healing rate of about 90% at 8 weeks after eradication therapy (11) rebamipide (2-(4- chlorobenzoylamino)-3-\[2-(1h)-quinolinon-4-yl\] propionic acid) prevents gastric ulcer formation by inhibiting neutrophil activation. rebamipide stimulates prostaglandin generation in the gastric mucosa, resulting in stimulation of mucus secretion. rebamipide inhibits h. pylori adhesion to the gastric epithelial cells.(12) the primary aim of study to evaluate whether rebamipide could improve success rates of anti-h. pylori treatment .

Eligibility criteria:
inclusion criteria: 1. 20 years of age or older, 2. ulcer size, 5 mm or more in longest diameter, 3. single ulcer, 4. h. pylori positively. exclusion criteria: * use of medications such as ppis, h2-receptor antagonists, other gastroprotective drugs, or nonsteroidal anti-inflammatory drugs within a week prior to the start of the trial, (2) previous eradication therapy for h. pylori, (3) acute or duodenal ulcer, (4) gastric ulcer with high risk of massive bleeding
breinzorg: feasibility study into an online lifestyle platform for mci and scd

Conditions: Mild Cognitive Impairment; Cognitive Decline

Summary: dementia is the most common disease in older individuals and this century's biggest healthcare challenge. many patients who visit the memory clinic with memory complaints do not have dementia but instead are diagnosed with mild cognitive impairment (mci) or subjective cognitive decline (scd). mci or scd may be a pre-dementia stage. many patients with mci or scd often leave their consultation with unanswered questions, and unsure what they, themselves can do to reduce dementia risk. patients with mci and scd have a heightened risk of developing dementia. therefore, this group would possibly benefit most from preventive strategies. around 40% of dementia cases is attributable to modifiable factors. thus, managing a healthy lifestyle may reduce dementia risk. to answer the information request many patients have when leaving the memory clinic and to fill the knowledge gap an online tool has been developed. the goal of this mixed-method feasibility study is to investigate the usability, feasibility, patient experience, and effectiveness of the personalized, multi-domain online website in older adults with mci or scd. the main questions it aims to answer are: * is the new website being used by the target population? * how does the target population experience the use of the website? * what is the effect of using the website? participants will have access to the website and are free to use the website in any way they want.


Eligibility criteria:
inclusion criteria: * visited a memory clinic; * recent (no longer than 4 months) diagnosis of mci or scd according to the guidelines used in the memory clinic; * \>60 years of age; * sufficient fluency in dutch; * internet access at home and a working e-mail address; * sufficient hearing and vision to read, watch and hear content on the website. exclusion criteria: * diagnosis of dementia according to the guidelines of the memory clinic; * any condition to hinder successful 6-month follow-up; * diagnosis of major depression; * coincident participation in any other intervention trial at time of pre-screening.
pathophysiologic hemodynamics after primary unilateral total hip arthroplasty in patients receiving aceis and arbs

Conditions: Orthostatic Intolerance; Orthostatic Hypotension

Summary: incidence and pathophysiologic hemodynamics of postoperative orthostatic intolerance and orthostatic hypotension in patients receiving antihypertensives

early postoperative mobilization is essential for rapid functional recovery after surgery and it is considered a cornerstone in the so-called fast track multimodal perioperative approach, which includes early ambulation, oral nutrition, multimodal opioid-sparing analgesia and optimized fluid therapy. this strategy has improved patient outcome after surgery and reduced hospital length of stay. immobilization after surgery is associated with increased risk of complications including venous thromboembolism (deep venous thrombosis, pulmonary embolism), muscle wasting, pneumonia and atelectasis, thereby impending convalescence. however, early postoperative mobilization can be delayed due to failed orthostatic cardiovascular regulation, resulting in postoperative orthostatic hypotension (oh), defined as a decrease in systolic blood pressure \> 20 mmhg or diastolic blood pressure \> 10 mmhg or postoperative orthostatic intolerance (oi), characterized by dizziness, nausea, vomiting, visual disturbances or syncope. previous studies investigating the incidence and pathophysiology of postoperative oi and oh included mixed patient populations. hitherto no studies have been performed looking into the incidence and pathophysiologic hemodynamics of postoperative oi and oh specifically in patients receiving angiotensin-converting enzyme inhibitors (aceis) and angiotensin ii receptor blockers (arbs), antihypertensive agents with potential effects on cardiovascular compensatory functions. the current study aims therefore to estimate the incidence and gain knowledge on pathophysiological hemodynamics of postoperative oi and oh in patients receiving aceis and arbs.

Eligibility criteria:
inclusion criteria: * patients undergoing primary unilateral total hip arthroplasty (tha) in spinal anaesthesia in standardized fast-track setting * habitual use of angiontensin-converting enzyme inhibitors (aceis) and/or angiotensin 2 receptor blockers (arbs) on any indication * patients \> 18 * patients that understand and speak danish * patients that have provided written informed consent exclusion criteria: * alcohol abuse * any type of substance abuse * chronic pain treated by habitual use of opioids * habitual use of anxiolytic, antidepressant and/or antipsychotic drugs * history of cerebral apoplexy or transitory cerebral ischemia * history of previous orthostatic intolerance or hypotension * history of diabetes mellitus * history of following diseases of the autonomic nervous system: parkinson disease, multiple sclerosis, multiple system atrophy, autonomic neuropathies * cognitive dysfunction * dementia * american society of anesthesiologists (asa) \> 3

Keywords: orthostatic hypotension orthostatic intolerance postoperative period antihypertensives autonomic dysfunction
observational study of hiv infection in participants of seroconvert during dapivirine vaginal ring trials

Conditions: HIV Infections

Summary: the purpose of this trial is to determine if exposure to arv-containing investigational products in ipm clinical trials will impact the natural history of hiv infection as measured by the virologic, immunologic and clinical outcomes of participants who become hiv-positive during the ipm 027 trial.


Eligibility criteria:
inclusion criteria: * recent hiv seroconversion during participation in ipm 027, according to the hiv testing algorithm of that trial * ability and willingness to provide informed consent * willingness to give the research centre permission to share information with the primary health care provider (phcp), and willingness to sign approved site-specific documentation to facilitate such sharing. exclusion criteria: * any condition that, in the opinion of the investigator, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Keywords: hiv infections anti-hiv agents hiv-1
a study to investigate the use of golimumab (simponi®) in participants with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis (p06554)

Conditions: Arthritis, Rheumatoid; Arthritis, Psoriatic; Spondylitis, Ankylosing

Summary: this is a study to assess the use of golimumab (simponi®) in participants with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. the study objective is to evaluate the clinical safety of golimumab (simponi®) under real-life, clinical practice conditions as assessed by the incidence and type of (serious) adverse events and changes in clinical status of participants as assessed by clinical parameters.


Eligibility criteria:
inclusion criteria: * has rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis and treatment with simponi® by autoinjector device is to be initiated for the first time exclusion criteria: * no specific exclusion criteria
thoracic lymphatic pump technique exercises chronic mechanical low back pain

Conditions: Low Back Pain, Mechanical

Summary: the purpose of the study is to compare between the combined effect of thoracic lymphatic pump technique with exercises and exercises alone on pain intensity using visual analogue scale (vas), lumbar spine mobility using modified-modified schober test (mmst) and functional disability level using oswestary disability index (odi) on patients with cmlbp.

study design: this study will be randomizaed controlled trail.1. participants:forty-two patients with chronic mechanical low back pain. age:20-45. th sample size population: was calculated using the g\*power program 3.1.9 (g power program version 3.1, heinrich-heine-university, düsseldorf, germany) for one tailed test. sample size calculation based on f tests (anova: special effects and interactions), type i error (a) = 0.05, power (1-ß error probability) = 0.80, pillai v = 0.3300000 and effect size f (v) = 0.8 with 2 independent groups comparison for 3 major variable outcomes. the appropriate minimum sample size for this study was 42 patients (21 patients in each group). procedure:first, the purpose of the study will be explained to the patients and the procedures are fully explained. then, patients will be asked to participate in the study. if they accepted, an informed consent form will be signed and randomly assigned in one of two groups (by closed envelope method). all subjects will be evaluated for their pain intensity,lumbar spine mobility and functional disability level. all patients will be tested before and after the treatment program (12 treatment sessions, 3 sessions per week for 4 weeks). each patient will receive exercises (stretching and strengthening exercises) for the control group (a), the stretching exercises include (hamstring stretching- lower back stretching) and the strengthening exercises- include (abdominal curl up- supine bridging-trunk extension). for the experimental group (b), they will receive exercises (stretching and strengthening exercises) then the thoracic lymphatic pump technique.

Eligibility criteria:
inclusion criteria: * patients (both genders) with a chief complain of chronic mechanical low back pain without leg pain (al sulaimy et al., 2018). * age of the patient 20- 45 years old (al sulaimy et al., 2018). * pain more than three months exclusion criteria: * patient with spondylolysis (steele et al., 2016). * patient with tumor, infection (ulger et al., 2017). * patient with cauda equina syndrome who need urgent surgery (ulger et al., 2017). * patients with previous lumber surgery (amundsen et al., 2018). * patient with deep venous thrombosis (dvt) (alves et al., 2020). * patient with congestive heart failure (alves et al., 2020). * patient with renal failure (forner-cordero et al., 2021). * patient with uncontrolled hypertension (forner-cordero et al., 2021).
reliability and validity of pittsburgh rehabilitation participation scale during robot therapy

Conditions: Stroke

Summary: reliability and validity of pittsburgh rehabilitation participation scale during robot therapy among patients with stroke


Eligibility criteria:
inclusion criteria: * patients with stroke or traumatic brain injury * inpatient in rehabilitation center exclusion criteria: * brain tumor * spinal cord injury

Keywords: participation robot scale rehabilitation
treatment for cubital tunnel syndrome

Conditions: Cubital Tunnel Syndrome

Summary: the researchers want to find out the best treatment for cubital tunnel. the researchers establish the degree of nerve compression and then the patients are randomised to different treatment alternatives, ranging from conservative to operative treatments. the study is performed at 5 different hospitals in norway.


Eligibility criteria:
inclusion criteria: * patients with cubital tunnel syndrome exclusion criteria: * rheumatoid arthritis (ra) * osteoarthrosis * varus or valgus deformities at elbow

Keywords: cubital tunnel treatment nerve compression
assessing response to treatment in non-hodgkin's lymphoma patients using 64cu-dota-rituximab pet/ct

Conditions: Non-Hodgkin's Lymphoma

Summary: rituximab is an antibody targeted against the cd20 antigen found primarily on b-cells. therefore, an imaging agent targeting cd20 expression may provide a more accurate evaluation of extent of disease and response to therapy than the current standard of care, f-18 fdg pet/ct. the main purpose of the study is to investigate a new pet/ct imaging probe for detection and follow up of lymphoma. following are the 3 aims of the study: a) phase i testing in lymphoma patients of cu-64 labelled rituxan for defining normal tracer biodistribution, stability, pharmacokinetics and radiation dosimetry; b) comparison of cu-64 rituxan and f-18 fdg pet/ct in lymphoma patients; c) evaluation of changes in uptake of cu-64 rituxan in response to rituximab-based treatment in cd20-positive b-cell nhl


Eligibility criteria:
inclusion criteria: * patients must have a diagnosis of cd20-positive b-cell nhl and a staging 18f fdg pet/ct prior to the 64cu-dota-rituximab pet/ct * patients must understand and voluntarily sign an informed consent form after the contents have been fully explained to them * patients must be scheduled for rituximab-based therapy * patients must be older than 18-year-old exclusion criteria: * patients who cannot complete a pet/ct scan * pregnant women * patients participating in other research protocols will be excluded from this study
photobiomodulation in salivary production of patients with xerostomy

Conditions: Xerostomia

Summary: xerostomia is a quantitative and qualitative alteration of saliva, a symptom present in individuals who make continuous use of medications to control chronic diseases, including hypertension. difficulties in mastication, swallowing, phonation and palate are present, besides oral burning syndrome, periodontal disease, root caries and bad breath that will interfere in the quality of life, making it difficult to socialize in society. currently, the methods presented for treatment of xerostomia are palliative, so their use does not consist of an effective treatment. the objective of this study is to evaluate the efficacy of photobiomodulation in the production of saliva in patients with xerostomia induced by antihypertensive drugs. the method consists in the application of the low intensity laser in the three pairs of salivary glands - parotid, submandibular and sublingual. the parameters that will be used are: laser diode argaal, dmc, 808nm, 4j per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mw/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. the exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. the radiant exposure will be 142j/cm2. the control group will have a simulation of the application of the laser, with the device turned off. because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off. in the group that receives the photobiomodulation the device will have its timer turned off, to avoid the perception of sound difference. at the end of the sessions, a sample of saliva will be collected, which will be compared to the initial sample.


Eligibility criteria:
inclusion criteria: * hypertensive patients using antihypertensive drugs who present xerostomia; * hospitalized in the high-stay unit of the mandaqui hospital complex; * patients who sign the free and informed consent form. exclusion criteria: * patients with cancer in the oral region; * patients receiving radiation therapy; * patients with sjögren's syndrome; * diabetics and those with any type of photosensitivity.